In Vivo Activities of Farnesyl Pyrophosphate Synthase Inhibitors against Leishmania donovani and Toxoplasma gondii
Open Access
- 1 March 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (3) , 929-931
- https://doi.org/10.1128/aac.46.3.929-931.2002
Abstract
The in vivo activities of three bisphosphonates were determined against Leishmania donovani and Toxoplasma gondii. Alendronate was essentially inactive against both parasites. Pamidronate was active against L. donovani by intravenous administration. Risedronate had a 50% effective dosage of five 2.6-mg/kg of body weight intraperitoneal doses against L. donovani-infected mice but was less effective against T. gondii-infected mice.Keywords
This publication has 6 references indexed in Scilit:
- Bisphosphonates Are Potent Inhibitors of Trypanosoma cruzi Farnesyl Pyrophosphate SynthasePublished by Elsevier ,2001
- Bisphosphonates Inhibit the Growth ofTrypanosomabrucei,Trypanosomacruzi,Leishmaniadonovani,Toxoplasmagondii, andPlasmodiumfalciparum: A Potential Route to ChemotherapyJournal of Medicinal Chemistry, 2001
- A Peptide Prodrug Approach for Improving Bisphosphonate Oral AbsorptionJournal of Medicinal Chemistry, 2000
- Trypanosoma cruzi Contains Major Pyrophosphate Stores, and Its Growth in Vitro and in Vivo Is Blocked by Pyrophosphate AnalogsJournal of Biological Chemistry, 1999
- The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infectionAntimicrobial Agents and Chemotherapy, 1997
- The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma bruceiJournal of Antimicrobial Chemotherapy, 1996